J&J and Legend’s Carvykti scores early line approval for MM by FDA
J&J and Legend’s CAR-T cell therapy has been approved as a second-line therapy for patients with multiple myeloma (MM).
J&J and Legend’s CAR-T cell therapy has been approved as a second-line therapy for patients with multiple myeloma (MM).
What's Your Reaction?
